BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Drug Development

  Celsion Announces Publication of the HEAT Study Manuscript in the High Impact Journal, Clinical Cancer Research

  The study was published in Clinical Cancer Research, a high impact, peer-reviewed medical journal.

  October 16, 2017

   · 

  11 min read
• Drug Development

  Zogenix’s Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy

  Findings Presented by Zogenix at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C.

  October 16, 2017

   · 

  5 min read
• Drug Development

  Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase I Study of Autologous ATA190 in Patients with Progressive MS

  Five of eight progressive MS patients who received the full course of autologous ATA190 experienced clinical improvements.

  October 16, 2017

   · 

  8 min read
• Business

  Silicon Therapeutics Appoints Dr. Christopher Winter As Chief Of R&D

  Silicon Therapeutics announced today the appointment of Dr. Christopher Winter as Chief of R&D. Dr. Winter joins Silicon Therapeutics from Sanofi.

  October 16, 2017

   · 

  3 min read
• Drug Development

  Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812

  Cognition announced that the FDA has granted Fast Track designation to its investigational drug CT1812 for the treatment of patients with Alzheimer’s disease.

  October 16, 2017

   · 

  3 min read
• 

  Job Trends

  Mallinckrodt Created 330 New Jobs With Specialty Brands Office In NJ

  The new office is home to nearly 500 Jobs supporting the company’s hospital therapies and autoimmune and rare diseases businesses.

  October 16, 2017

   · 

  5 min read
• 

  Drug Development

  TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase III Trial

  Follow-up meeting with the FDA is expected before year end.

  October 16, 2017

   · 

  5 min read
• Drug Development

  TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase III Trial

  TG Therapeutics announced today that it has completed full enrollment in the UNITY-CLL Phase 3 clinical trial.

  October 16, 2017

   · 

  6 min read
• Biotech Bay

  Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected For Late Breaking Oral Presentation At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting

  Five Prime Therapeutics today announced that the abstract featuring data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, cabiralizumab (FPA008), with Opdivo® (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor.

  October 16, 2017

   · 

  2 min read
• Drug Development

  ZIOPHARM Oncology Announces First Patient Dosed in New Phase I Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors

  ZIOPHARM announced that the first patient has been dosed in a new Phase 1 study of Ad-RTS-hIL-12 with veledimex for the treatment of pediatric brain tumors.

  October 16, 2017

   · 

  7 min read